These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

133 related items for PubMed ID: 10477163

  • 1. Selective cell kill of the combination of gemcitabine and cisplatin in multilayered postconfluent tumor cell cultures.
    Padrón JM, van Moorsel CJ, Bergman AM, Smitskamp-Wilms E, van der Wilt CL, Peters GJ.
    Anticancer Drugs; 1999 Jun; 10(5):445-52. PubMed ID: 10477163
    [Abstract] [Full Text] [Related]

  • 2. Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines.
    van Moorsel CJ, Pinedo HM, Veerman G, Bergman AM, Kuiper CM, Vermorken JB, van der Vijgh WJ, Peters GJ.
    Br J Cancer; 1999 Jun; 80(7):981-90. PubMed ID: 10362105
    [Abstract] [Full Text] [Related]

  • 3. Combination chemotherapy studies with gemcitabine and etoposide in non-small cell lung and ovarian cancer cell lines.
    van Moorsel CJ, Pinedo HM, Veerman G, Guechev A, Smid K, Loves WJ, Vermorken JB, Postmus PE, Peters GJ.
    Biochem Pharmacol; 1999 Feb 15; 57(4):407-15. PubMed ID: 9933029
    [Abstract] [Full Text] [Related]

  • 4. Synergistic interaction between cisplatin and gemcitabine in vitro.
    Bergman AM, Ruiz van Haperen VW, Veerman G, Kuiper CM, Peters GJ.
    Clin Cancer Res; 1996 Mar 15; 2(3):521-30. PubMed ID: 9816199
    [Abstract] [Full Text] [Related]

  • 5. Interaction between cisplatin and gemcitabine in vitro and in vivo.
    Peters GJ, Bergman AM, Ruiz van Haperen VW, Veerman G, Kuiper CM, Braakhuis BJ.
    Semin Oncol; 1995 Aug 15; 22(4 Suppl 11):72-9. PubMed ID: 7481849
    [Abstract] [Full Text] [Related]

  • 6. Effects of gemcitabine on cis-platinum-DNA adduct formation and repair in a panel of gemcitabine and cisplatin-sensitive or -resistant human ovarian cancer cell lines.
    Peters GJ, Van Moorsel CJ, Lakerveld B, Smid K, Noordhuis P, Comijn EC, Weaver D, Willey JC, Voorn D, Van der Vijgh WJ, Pinedo HM.
    Int J Oncol; 2006 Jan 15; 28(1):237-44. PubMed ID: 16328001
    [Abstract] [Full Text] [Related]

  • 7. Effect of gemcitabine and cis-platinum combinations on ribonucleotide and deoxyribonucleotide pools in ovarian cancer cell lines.
    Van Moorsel CJ, Smid K, Voorn DA, Bergman AM, Pinedo HM, Peters GJ.
    Int J Oncol; 2003 Jan 15; 22(1):201-7. PubMed ID: 12469205
    [Abstract] [Full Text] [Related]

  • 8. Schedule-dependent pharmacodynamic effects of gemcitabine and cisplatin in mice bearing Lewis lung murine non-small cell lung tumours.
    van Moorsel CJ, Pinedo HM, Smid K, Comijn EM, Voorn DA, Veerman G, Lakerveld B, Van der Vijgh WJ, Giaccone G, Postmus PE, Peters GJ.
    Eur J Cancer; 2000 Dec 15; 36(18):2420-9. PubMed ID: 11094319
    [Abstract] [Full Text] [Related]

  • 9. Expression of ERCC1 antisense RNA abrogates gemicitabine-mediated cytotoxic synergism with cisplatin in human colon tumor cells defective in mismatch repair but proficient in nucleotide excision repair.
    Yang LY, Li L, Jiang H, Shen Y, Plunkett W.
    Clin Cancer Res; 2000 Mar 15; 6(3):773-81. PubMed ID: 10741696
    [Abstract] [Full Text] [Related]

  • 10. Combination chemotherapy studies with gemcitabine.
    van Moorsel CJ, Veerman G, Bergman AM, Guechev A, Vermorken JB, Postmus PE, Peters GJ.
    Semin Oncol; 1997 Apr 15; 24(2 Suppl 7):S7-17-S7-23. PubMed ID: 9194475
    [Abstract] [Full Text] [Related]

  • 11. Scheduling of gemcitabine and cisplatin in Lewis lung tumour bearing mice.
    van Moorsel CJ, Pinedo HM, Veerman G, Vermorken JB, Postmus PE, Peters GJ.
    Eur J Cancer; 1999 May 15; 35(5):808-14. PubMed ID: 10505043
    [Abstract] [Full Text] [Related]

  • 12. Postconfluent multilayered cell line cultures for selective screening of gemcitabine.
    Smitskamp-Wilms E, Pinedo HM, Veerman G, Ruiz van Haperen VW, Peters GJ.
    Eur J Cancer; 1998 May 15; 34(6):921-6. PubMed ID: 9797708
    [Abstract] [Full Text] [Related]

  • 13. Pharmacokinetic schedule finding study of the combination of gemcitabine and cisplatin in patients with solid tumors.
    van Moorsel CJ, Kroep JR, Pinedo HM, Veerman G, Voorn DA, Postmus PE, Vermorken JB, van Groeningen CJ, van der Vijgh WJ, Peters GJ.
    Ann Oncol; 1999 Apr 15; 10(4):441-8. PubMed ID: 10370787
    [Abstract] [Full Text] [Related]

  • 14. In vitro study on the schedule-dependency of the interaction between pemetrexed, gemcitabine and irradiation in non-small cell lung cancer and head and neck cancer cells.
    Wouters A, Pauwels B, Lardon F, Pattyn GG, Lambrechts HA, Baay M, Meijnders P, Vermorken JB.
    BMC Cancer; 2010 Aug 19; 10():441. PubMed ID: 20723210
    [Abstract] [Full Text] [Related]

  • 15. Schedule dependence of sensitivity to 2',2'-difluorodeoxycytidine (Gemcitabine) in relation to accumulation and retention of its triphosphate in solid tumour cell lines and solid tumours.
    Ruiz van Haperen VW, Veerman G, Boven E, Noordhuis P, Vermorken JB, Peters GJ.
    Biochem Pharmacol; 1994 Oct 07; 48(7):1327-39. PubMed ID: 7945430
    [Abstract] [Full Text] [Related]

  • 16. Interaction of gemcitabine with paclitaxel and cisplatin in human tumor cell lines.
    Theodossiou C, Cook JA, Fisher J, Teague D, Liebmann JE, Russo A, Mitchell JB.
    Int J Oncol; 1998 Apr 07; 12(4):825-32. PubMed ID: 9499442
    [Abstract] [Full Text] [Related]

  • 17. The efficacy of 2',2'-difluorodeoxycytidine (gemcitabine) combined with interferon in human renal cell carcinoma cell lines.
    Rohde D, Hayn HK, Blatter J, Jakse G.
    Int J Oncol; 1998 Jun 07; 12(6):1361-6. PubMed ID: 9592200
    [Abstract] [Full Text] [Related]

  • 18. Sensitivity to ionizing radiation and chemotherapeutic agents in gemcitabine-resistant human tumor cell lines.
    van Bree C, Castro Kreder N, Loves WJ, Franken NA, Peters GJ, Haveman J.
    Int J Radiat Oncol Biol Phys; 2002 Sep 01; 54(1):237-44. PubMed ID: 12182997
    [Abstract] [Full Text] [Related]

  • 19. Collateral sensitivity to gemcitabine (2',2'-difluorodeoxycytidine) and cytosine arabinoside of daunorubicin- and VM-26-resistant variants of human small cell lung cancer cell lines.
    Bergman AM, Munch-Petersen B, Jensen PB, Sehested M, Veerman G, Voorn DA, Smid K, Pinedo HM, Peters GJ.
    Biochem Pharmacol; 2001 Jun 01; 61(11):1401-8. PubMed ID: 11331076
    [Abstract] [Full Text] [Related]

  • 20. Cross-resistance in the 2',2'-difluorodeoxycytidine (gemcitabine)-resistant human ovarian cancer cell line AG6000 to standard and investigational drugs.
    Bergman AM, Giaccone G, van Moorsel CJ, Mauritz R, Noordhuis P, Pinedo HM, Peters GJ.
    Eur J Cancer; 2000 Oct 01; 36(15):1974-83. PubMed ID: 11000580
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.